IL136903A0 - Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals - Google Patents

Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals

Info

Publication number
IL136903A0
IL136903A0 IL13690399A IL13690399A IL136903A0 IL 136903 A0 IL136903 A0 IL 136903A0 IL 13690399 A IL13690399 A IL 13690399A IL 13690399 A IL13690399 A IL 13690399A IL 136903 A0 IL136903 A0 IL 136903A0
Authority
IL
Israel
Prior art keywords
lipooligosaccharide
branhamella
moraxella
mammals
prevention
Prior art date
Application number
IL13690399A
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IL136903A0 publication Critical patent/IL136903A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL13690399A 1998-01-13 1999-01-12 Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals IL136903A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7148398P 1998-01-13 1998-01-13
PCT/US1999/000590 WO1999036086A1 (en) 1998-01-13 1999-01-12 Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals

Publications (1)

Publication Number Publication Date
IL136903A0 true IL136903A0 (en) 2001-06-14

Family

ID=22101617

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13690399A IL136903A0 (en) 1998-01-13 1999-01-12 Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals

Country Status (9)

Country Link
EP (1) EP1047447A1 (en)
JP (1) JP2002509115A (en)
KR (1) KR20010034124A (en)
CN (1) CN1288384A (en)
AU (2) AU2221299A (en)
BR (1) BR9906902A (en)
CA (1) CA2315746A1 (en)
IL (1) IL136903A0 (en)
WO (1) WO1999036086A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089839A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
US20040126381A1 (en) 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
WO2006085910A2 (en) * 2004-06-04 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Endotoxin-free moraxella catarrhalis
CN104592365B (en) * 2013-11-01 2019-06-14 中国人民解放军军事医学科学院毒物药物研究所 Soman antigen, soman vaccine and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7701098A (en) * 1997-05-28 1998-12-30 Michael A. Apicella Laft mutants of pathogenic gram-negative bacteria

Also Published As

Publication number Publication date
CA2315746A1 (en) 1999-07-22
KR20010034124A (en) 2001-04-25
AU2003200964A1 (en) 2003-06-12
BR9906902A (en) 2000-10-17
CN1288384A (en) 2001-03-21
EP1047447A1 (en) 2000-11-02
JP2002509115A (en) 2002-03-26
AU2003200964B2 (en) 2004-11-11
WO1999036086A1 (en) 1999-07-22
AU2221299A (en) 1999-08-02
AU2003200964A8 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
HUP9903947A3 (en) Purification of neurotrophins
EP1098628A4 (en) Casein formulations for the delivery of bioactive constituents
ID16038A (en) PHARMACEUTICAL COMPOSITION FOR IMMUNOMODULATION
SI1089733T1 (en) Use of optically pure (+)-norcisapride for treating irritable bowel syndrome
HK1023371A1 (en) Compositions and methods for treating viral infections
IL121041A0 (en) Immunogenic compositions for induction of anti-tumor immunity
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
IL136903A0 (en) Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals
IL134627A0 (en) Method of protecting against chronic infections
AU4033199A (en) Polypeptides from moraxella (branhamella) catarrhalis
EP1135137A4 (en) Copolymer compositions for treating viral infections
HU9501011D0 (en) Treatment of h. pylori infections
HUP0000588A3 (en) Preparation of purified (poly)peptides
IL111102A0 (en) Vaccine for branhamella catarrhalis
GB9419571D0 (en) Treatment of oral infections
HUP0102853A3 (en) Compounds from moraxella catarrhalis
HUP0103945A3 (en) Moraxella catarrhalis basb034 polypeptides and uses thereof
AU5091898A (en) Method of vaccinating infants against infections
GB9612990D0 (en) Compositions and methods for the treatment of chronic infections
GB9602444D0 (en) Pharmaceutical compositions for the prevention or treatment of retrovirus infections
AU5977900A (en) Cloning of basb110 antigen from moraxella (branhamella) catarrhalis
GB9108909D0 (en) Siloxane ablative compositions
IL118651A0 (en) Composition for the treatment of viral infections
AU4260099A (en) Compounds from moraxella catarrhalis
GB9603657D0 (en) Improvements in the treatment of vaginal infections